Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL

Findings from the GIMEMA ALL2820 study

#	Наименование новости	Информативность	Дата публикации
1	Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature review	13.23	20-08-2026
2	Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL	2.16	27-08-2026
3	Российский препарат «Сибкордия» получил регистрацию для лечения лейкоза	9.9	23-07-2026
4	Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	11.9	01-07-2026
5	NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	5	27-08-2026
6	Nivolumab-Ipilimumab for Gastric/Gastroesophageal Junction Adenocarcinoma	17.25	15-10-2026
7	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	18.85	30-07-2026
8	Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults	5.92	01-07-2026
9	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	14.28	01-01-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 21.16. Источник: www.esmo.org.

Найдите то, что Вас интересует